2C-D

2C-series compounds produce cardiovascular stimulation including hypertension and tachycardia (Dean et al. 2013). These effects may pose risk in individuals with pre-existing cardiovascular disease, hypertension, or arrhythmias.

Seizures have been documented in 2C-series intoxication presentations (Dean et al. 2013). Individuals with epilepsy or seizure disorders face elevated risk.

All serotonergic psychedelics including 2C-D are contraindicated in individuals with a personal or family history of psychotic disorders (schizophrenia, schizoaffective disorder). 5-HT2A activation may trigger psychotic decompensation.

Psychedelic use carries risk of manic episode precipitation in individuals with bipolar disorder. Risk may be lower with 2C-D's weak agonism compared to more potent psychedelics, but no substance-specific data exist.

No data on teratogenicity, embryotoxicity, or effects on fetal development exist for 2C-D. Standard precautionary contraindication applies.

Concurrent use of classical MAOIs with 2C-D creates convergent serotonergic stimulation: exogenous MAO inhibition, 2C-D's own MAO inhibitory activity, and direct 5-HT2A agonism. This combination carries high risk of serotonin syndrome.

Combining 2C-D with serotonergic medications (SSRIs, SNRIs, tramadol, triptans, St. John's Wort) elevates serotonin syndrome risk through convergent mechanisms. Tramadol is flagged as particularly dangerous due to additional seizure threshold lowering.